Data with topical pravibismane for infected chronic diabetic foot ulcers in first-to-podium research at SAWC Spring/WHS
Microbion Phase 2 study shows favorable safety and early efficacy data, with 46.7% of patients treated achieving complete wound closure. GRAPEVINE, TX, UNITED STATES, May 2, 2025 /EINPresswire.com/ -- A Microbion Corporation exploratory Phase 2a study …